Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...

Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait ...

Learn more about whether Travere Therapeutics, Inc. or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Twist Bioscience Corporation or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Bristol-Myers Squibb's key drugs are losing patent protection, while more recently launched drugs are struggling to meet peak revenue expectations. Learn more about BMY stock here.